Hao Qi Jun Pharmaceutical

Hao Qi Jun Pharmaceutical is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the discovery and development of next-generation small molecule therapeutics. The company's primary focus lies in metabolic diseases, particularly type 2 diabetes and obesity, as well as oncology. Its lead candidate, HQJ-181, is a potent and selective oral small molecule Glucagon-like peptide 1 receptor (GLP-1R) agonist that has progressed into Phase 2 clinical trials. By focusing on oral delivery, Hao Qi Jun aims to improve patient compliance and accessibility compared to traditional injectable peptide therapies. The company was founded by Dr. Hao Jun, an expert in medicinal chemistry, and is supported by prominent venture capital firms. Hao Qi Jun continues to expand its pipeline with innovative candidates targeting significant unmet medical needs in the global healthcare market.